PRLB Proto Labs 10-Q 2026-09-30 section summaries

Proto Labs, Inc. — quarter and nine months ended September 30, 2026

Consolidated results

Q3 revenue grew 14.0%; gross margin was 44.5% versus 45.3%, while operating margin improved to 9.4% from 6.5%. For 9M, revenue increased 11.7%, gross margin improved to 45.5% from 44.6%, and operating income nearly doubled. Operating expenses included $0.434M of Q3 restructuring and transformation costs (all in Europe). For 9M, they included $2.779M of restructuring and transformation costs and $0.937M of exit/disposal costs, versus none and $0.151M, respectively, in 9M 2025.

Revenue and segment performance

Growth was led by CNC Machining and Injection Molding; Sheet Metal revenue declined.

Corporate Unallocated costs primarily reflect R&D, G&A and other unallocated expenses. Europe’s 9M operating loss included $2.448M of restructuring and transformation costs and $0.937M of exit/disposal costs; Corporate Unallocated included $0.331M of restructuring costs.

Cash flow and capital spending

Despite higher net income, operating cash flow declined, with cash use from accounts receivable of $21.625M versus $11.265M and from inventory of $2.267M versus $2.017M; accrued liabilities provided $7.023M versus $15.907M. Increased purchases of marketable securities contributed to investing outflows. Financing outflows narrowed as share repurchases fell to $10.038M from $36.732M. Cash increased $22.954M in 9M 2026, versus a $15.351M increase in 9M 2025.

Balance sheet and liquidity

At September 30, other intangible assets comprised $0 non-compete agreement, $1.709M software technology and $13.954M software platform. Marketable securities had $41.702M amortized cost and $41.269M fair value, including $0.433M of gross unrealized losses and no unrealized gains; they were primarily agency, corporate debt, municipal and Treasury instruments, with maturities within five years. The company reported no borrowings on the balance sheet. Accounts receivable was $99.256M, with a $2.601M credit-loss allowance; net inventory was $16.538M, with a $1.224M obsolescence allowance.

Long-lived assets totaled $206.932M, down from $215.261M at year-end, including $165.277M in the U.S. and $41.655M in Europe. 9M additions rose to $15.539M from $6.792M, primarily U.S. additions of $14.358M versus $5.929M. Depreciation and amortization declined to $24.269M from $25.693M.

Shares, compensation and taxes

Common shares outstanding increased from 23,627,422 at December 31, 2025 to 23,871,875 at September 30, 2026. Weighted-average diluted shares were 24,438,800 versus 24,191,039 in Q3, and 24,398,409 versus 24,249,669 for 9M. Stock-based compensation was $3.351M in Q3 versus $3.677M and $10.658M for 9M versus $11.928M. Nonvested awards carried $29.8M of unrecognized compensation cost: $3.7M for options, $17.3M for RSUs and $8.8M for PSUs. Outstanding awards included 265,741 options (103,385 exercisable), 563,790 RSUs and 223,104 PSUs. The 2022 incentive plan’s share authorization increased by 395,000 shares in May 2026.

The effective tax rate was 27.4% in Q3 versus 29.6%, and 27.7% for 9M versus 33.5%. The lower 9M rate primarily reflected a more favorable geographic mix toward lower-tax jurisdictions and strong domestic pretax income. The Q3 decrease reflected an operating-rate catch-up credit, partly offset by lower excess tax benefits from stock compensation. Unrecognized tax benefits were $3.2M at September 30, 2026, versus $3.1M at December 31, 2025.

Q3 other comprehensive loss was $0.648M, including $0.434M of foreign-currency translation loss and $0.214M of unrealized investment losses; 9M OCI was a $2.960M loss versus $3.260M of OCI income in 2025. Accumulated other comprehensive loss ended Q3 at $23.936M, compared with $24.724M at the end of Q3 2025.

Protolabs — Q3 and nine months ended September 30, 2026

Protolabs’ revenue growth outpaced its decline in customer contacts, reflecting higher revenue per contact and a strategic shift toward larger customers. U.S. aerospace and defense demand was a notable source of strength. Gross margin fell in Q3 as personnel, materials and production costs rose, but expanded for the first nine months as cost of revenue grew more slowly than sales.

Consolidated results

All figures in $M.

Q3 revenue increased 14.0%, while operating income rose 63.9% and net income rose 63.0%. For 9M, revenue increased 11.7%, operating income 94.6% and net income 90.4%.

Revenue by product line

All figures in $M.

CNC machining was the largest product line and grew 16.4% for 9M. Q3 strength in U.S. aerospace and defense reflected demand across CNC machining, injection molding and 3D printing, as well as market-driven price increases.

Revenue by geography

All figures in $M.

Q3 U.S. revenue grew 14.7%; Europe grew 11.2%, partly offset by $0.3M of adverse foreign-exchange impact. For 9M, currency movements added $2.3M to international revenue, primarily from a stronger pound and euro.

Customers, costs and investment

Customer contacts fell 2.2% in Q3 and 4.2% for 9M, while revenue per contact rose 16.6% and 16.5%, respectively. Management attributed the shift primarily to customer mix and its focus on larger, more strategic accounts.

Q3 cost of revenue rose 15.6%, faster than sales, contributing to the margin decline. It included $5.4M of higher personnel and related costs, $4.8M of higher raw-material and production costs, and $1.4M of higher equipment and facility costs. Across 9M, cost of revenue rose 9.8%, with increases of $10.4M in personnel and related costs, $9.9M in raw materials and production costs, and $1.2M in equipment and facility costs.

Q3 marketing and sales expense was $24.528M versus $24.574M; R&D was $11.019M versus $10.705M; and G&A was $18.241M versus $17.163M. Restructuring and transformation expense was $0.434M in Q3 and $2.779M for 9M, versus none in the comparable 2025 periods. The 9M charge mainly comprised $1.7M of severance and $1.1M of professional services. Germany facility exit and disposal costs were $0.937M for 9M versus $0.151M, including a $0.9M write-down of an abandoned facility right-of-use asset. Total stock-based compensation was $3.351M in Q3 versus $3.677M, and $10.658M for 9M versus $11.928M.

The 9M effective tax rate declined to 27.7% from 33.5%, mainly due to geographic mix shifting toward lower-tax jurisdictions and strong domestic pretax income. The Q3 rate fell to 27.4% from 29.6%, primarily due to an operating-rate catch-up credit, partly offset by reduced excess stock-compensation tax benefits.

Cash flow and liquidity

All figures in $M; 9M periods.

Operating cash flow declined despite higher net income: a $17.1M year-over-year decrease in cash contribution from operating assets, liabilities and other items more than offset the $13.8M increase in net income. Financing outflow included $10.0M of common-stock repurchases and $6.1M of shares withheld for taxes, partly offset by $8.0M of equity-plan proceeds. The prior-year period included $36.7M of repurchases.

Cash and cash equivalents were $133.8M at September 30, 2026, up $23.0M from year-end 2025. The company expects existing cash and operating cash generation to cover working-capital and capital-expenditure needs for at least 12 months.

Management’s priorities include customer experience, innovation, production capacity and operational efficiency. It is redeploying restructuring savings into technology, automation, core systems and digital capabilities, and applying AI in pricing and sourcing, inspection, CNC toolpath verification and software development. Key sensitivities include labor and raw-material costs, production capacity and mix, pricing, manufacturing partners and foreign exchange.

Foreign-currency risk

Protolabs has unhedged foreign-currency exposure from its international operations. Revenue, production and sourcing costs, and operating expenses are primarily denominated in British pounds and euros. A stronger U.S. dollar generally harms operating results and cash flows; a stronger pound relative to the euro also has an adverse effect. Management expects exposure to increase with international expansion. A hypothetical 10% adverse exchange-rate move is not expected to materially affect financial position, but could materially affect operating results.

Exchange-rate changes had an unfavorable $0.3M impact on consolidated revenue in Q3 2026 versus Q3 2025, but a favorable $2.3M impact in 9M 2026 versus 9M 2025.

Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of quarter-end and provided reasonable assurance that required information was processed and reported on time and communicated to support timely disclosure decisions. No changes during the quarter materially affected, or were reasonably likely to materially affect, internal control over financial reporting.

Risk Factors

PRLB reported no material changes to the risk factors disclosed in its Form 10-K for the year ended December 31, 2025. This section contains no new financial metrics, business developments, or specific risk updates.

For the three months ended September 30, 2026, no directors or officers adopted, modified, or terminated a Rule 10b5-1 trading plan or a non-Rule 10b5-1 trading arrangement. This section reported no financial results or business developments.